NEW YORK (
CHANGE IN RATINGS
was upgraded at Wells Fargo to outperform from market perform. Stock has underperformed over the past four months, but Wells Fargo said it recently had a constructive meeting with management.
was downgraded at Jefferies to hold from buy. $8 price target. Sub scale handset business undercuts MDM opportunity, Jefferies said.
Blackberry was upgraded at Credit Suisse to neutral from underperform. $8 price target. Estimates slashed, but risks appear fully reflected in the stock, Credit Suisse said.
was downgraded at BMO Capital to underperform from market perform. $28 price target. Margins could be hurt, as the company invests more in the business, BMO Capital said.
was downgraded at Credit Suisse to neutral from outperform. $68 price target. Company is facing another transition year in 2015, Credit Suisse said.
was upgraded to buy.
was downgraded at Morgan Stanley to market perform from outperform. Company trades at a premium to its peers and growth is maturing, Morgan Stanley said.
was initiated with a buy rating at Bank of America/Merrill Lynch. $65 price target. Market should continue to grow over the coming quarters, BofA/Merrill said.
was downgraded at B. Riley to neutral from buy. Valuation call, as the stock is up 55% over the past five months, B. Riley said.
was initiated with a neutral rating at Goldman Sachs. Valuation call, based on a $26 price target, Goldman Sachs said.
Envision Healthcare was initiated with a buy rating and $32 price target at UBS. Accelerated growth will come from health reform and its increased exposure to outsourced physician services, UBS said.
was upgraded to buy at TheStreet Ratings.
was downgraded at Jefferies to hold from buy. $80 price target. Valuation call, said Jefferies.
was upgraded at Bank of America/Merrill Lynch to neutral from underperform. $15 price target. Company should benefit from better domestic pricing, BofA/Merrill said.
was upgraded at Goldman Sachs to buy from neutral. $34 price target. Company was also added to the Conviction List. Stock has lagged the market, but expect to see an inflection point in the consumer business, Goldman Sachs said.
was upgraded at Credit Suisse to neutral from underperform. $75 price target. Deal environment is improving, Credit Suisse said.
Read: Trading Options to Pay for College
was downgraded at Bank of America/Merrill Lynch to neutral from buy. $73 price target. Valuation call, as the stock has gained 37% year-to-date, BofA/Merrill said.
was upgraded at Credit Suisse to outperform from neutral. $215 price target. Company can exceed consensus expectations in the coming quarters, Credit Suisse said.
was initiated with a buy rating and $80 price target at Deutsche Bank. $80 price target. Estimates are above consensus, as management can unlock shareholder value, Deutsche Bank said.
was upgraded at Deutsche Bank to buy from hold. $125 price target. Company is leveraged to grow from the new health care exchange model, Deutsche Bank said.
was downgraded at Jefferies to hold from buy. $120 price target. Fundamental strength and EPS upside will persist, but pricing in most of the good news and outlook, Jefferies said.
STOCK COMMENTS / EPS CHANGES
price target was boosted at UBS to $80. Reflects a multiple slightly above the industry average, said UBS.
numbers were cut at Citigroup. Estimates were cut to reflect the significantly worse than expected earnings preannouncement, said Citigroup. Price target was reduced to $7.
estimates, price target were reduced at Keybanc. Shares are now seen reaching $79. Estimates were also cut, given lower industrial demand, Keybanc said. Buy rating.
>To submit a news tip, email:
and become a fan on
This article was written by a staff member of TheStreet.